Cholesterol-lowering drugs statins can slow the progression of multiple sclerosis, a study has found.
Cholesterol-lowering drugs statins can slow the progression of multiple sclerosis, a study has found.
The UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.Study participants received an 80 milligram daily dose of atorvastatin, marketed by Pfizer Inc. as Lipitor.
Although the study was small with only 81 participants and its primary endpoint, designed to evaluate MS progression in patients following their first attack, was not met, the researchers found over the 12-month course that 55.3 percent of participants did not develop new brain lesions when administered statins compared with 27.6 percent of the placebo group.
Study findings were presented by University of California, San Francisco researchers during the annual American Academy of Neurology scientific meeting in Toronto.
The trial was a phase II, multi-center, randomized, placebo-controlled follow up to a landmark study published by principal investigator Scott S. Zamvil, MD, PhD, associate professor of neurology at UCSF (Youssef, et al., Nature 2002), after his laboratory first observed that statins cause T cell immune modulation that could be beneficial in multiple sclerosis and other autoimmune diseases.
Co-led by Zamvil and Emmanuelle Waubant, MD, PhD, associate professor of neurology at the UCSF MS Center, the study tested whether the drug could be used to prevent conversion to definite multiple sclerosis in individuals who have had a first attack.
Advertisement
MS is considered an autoimmune disease where immune cells attack the central nervous system.
Advertisement
Source-ANI
SRM